Modernization of Chemical Risk Assessment to Make Use of Novel Toxicological Data

Overview

Journal Toxicol Appl Pharmacol

Specialties Pharmacology
Toxicology

Date 2020 Mar 23

PMID 32199875

Affiliations

Soon will be listed here.

References

Mezencev R, Subramaniam R . The use of evidence from high-throughput screening and transcriptomic data in human health risk assessments. Toxicol Appl Pharmacol. 2019; 380:114706. PMC: 9624462. DOI: 10.1016/j.taap.2019.114706. View

Page-Lariviere F, Crump D, OBrien J . Transcriptomic points-of-departure from short-term exposure studies are protective of chronic effects for fish exposed to estrogenic chemicals. Toxicol Appl Pharmacol. 2019; 378:114634. DOI: 10.1016/j.taap.2019.114634. View

Ankley G, Bennett R, Erickson R, Hoff D, Hornung M, Johnson R . Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment. Environ Toxicol Chem. 2010; 29(3):730-41. DOI: 10.1002/etc.34. View

Khadka K, Chen M, Liu Z, Tong W, Wang D . Integrating adverse outcome pathways (AOPs) and high throughput in vitro assays for better risk evaluations, a study with drug-induced liver injury (DILI). ALTEX. 2019; 37(2):187-196. DOI: 10.14573/altex.1908151. View

AbdulHameed M, Pannala V, Wallqvist A . Mining Public Toxicogenomic Data Reveals Insights and Challenges in Delineating Liver Steatosis Adverse Outcome Pathways. Front Genet. 2019; 10:1007. PMC: 6813744. DOI: 10.3389/fgene.2019.01007. View

Burnett S, Blanchette A, Grimm F, House J, Reif D, Wright F . Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019; 381:114711. PMC: 6745256. DOI: 10.1016/j.taap.2019.114711. View

Judson R, Houck K, Kavlock R, Knudsen T, Martin M, Mortensen H . In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ Health Perspect. 2010; 118(4):485-92. PMC: 2854724. DOI: 10.1289/ehp.0901392. View

Bell S, Angrish M, Wood C, Edwards S . Integrating Publicly Available Data to Generate Computationally Predicted Adverse Outcome Pathways for Fatty Liver. Toxicol Sci. 2016; 150(2):510-20. DOI: 10.1093/toxsci/kfw017. View

Fry R, Bangma J, Szilagyi J, Rager J . Developing novel in vitro methods for the risk assessment of developmental and placental toxicants in the environment. Toxicol Appl Pharmacol. 2019; 378:114635. PMC: 6684208. DOI: 10.1016/j.taap.2019.114635. View

10.

Pittman M, Edwards S, Ives C, Mortensen H . AOP-DB: A database resource for the exploration of Adverse Outcome Pathways through integrated association networks. Toxicol Appl Pharmacol. 2018; 343:71-83. PMC: 6104822. DOI: 10.1016/j.taap.2018.02.006. View

11.

Oki N, Nelms M, Bell S, Mortensen H, Edwards S . Accelerating Adverse Outcome Pathway Development Using Publicly Available Data Sources. Curr Environ Health Rep. 2016; 3(1):53-63. DOI: 10.1007/s40572-016-0079-y. View

12.

Kosnik M, Reif D . Determination of chemical-disease risk values to prioritize connections between environmental factors, genetic variants, and human diseases. Toxicol Appl Pharmacol. 2019; 379:114674. PMC: 6708494. DOI: 10.1016/j.taap.2019.114674. View

13.

Corton J, Kleinstreuer N, Judson R . Identification of potential endocrine disrupting chemicals using gene expression biomarkers. Toxicol Appl Pharmacol. 2019; 380:114683. DOI: 10.1016/j.taap.2019.114683. View

14.

Ankley G, Escher B, Hartung T, Shah I . Pathway-Based Approaches for Environmental Monitoring and Risk Assessment. Chem Res Toxicol. 2016; 29(11):1789-1790. DOI: 10.1021/acs.chemrestox.6b00321. View

15.

Edwards S, Tan Y, Villeneuve D, Meek M, McQueen C . Adverse Outcome Pathways-Organizing Toxicological Information to Improve Decision Making. J Pharmacol Exp Ther. 2015; 356(1):170-81. DOI: 10.1124/jpet.115.228239. View

16.

Dix D, Houck K, Martin M, Richard A, Setzer R, Kavlock R . The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci. 2006; 95(1):5-12. DOI: 10.1093/toxsci/kfl103. View

17.

Pollesch N, Villeneuve D, OBrien J . Extracting and Benchmarking Emerging Adverse Outcome Pathway Knowledge. Toxicol Sci. 2019; 168(2):349-364. PMC: 10545168. DOI: 10.1093/toxsci/kfz006. View

18.

Mortensen H, Senn J, Levey T, Langley P, Williams A . The 2021 update of the EPA's adverse outcome pathway database. Sci Data. 2021; 8(1):169. PMC: 8275694. DOI: 10.1038/s41597-021-00962-3. View

19.

Martens M, Verbruggen T, Nymark P, Grafstrom R, Burgoon L, Aladjov H . Introducing WikiPathways as a Data-Source to Support Adverse Outcome Pathways for Regulatory Risk Assessment of Chemicals and Nanomaterials. Front Genet. 2019; 9:661. PMC: 6308971. DOI: 10.3389/fgene.2018.00661. View

20.

Fasani R, Livi C, Choudhury D, Kleensang A, Bouhifd M, Pendse S . The Human Toxome Collaboratorium: A Shared Environment for Multi-Omic Computational Collaboration within a Consortium. Front Pharmacol. 2016; 6:322. PMC: 4756169. DOI: 10.3389/fphar.2015.00322. View